The survival duration for cancer patients treated with Sutent (sunitinib malate) varies based on the type of cancer and individual patient factors.
Renal Cell Carcinoma (RCC): Patients treated with Sutent have shown a median progression-free survival of approximately 11 months, compared to 5 months for those receiving interferon α (IFNα).
Gastrointestinal Stromal Tumors (GIST): Sutent has been shown to delay tumor progression by about 21 weeks, with a median progression-free survival of 24.1 weeks compared to 6 weeks for placebo.
Pancreatic Neuroendocrine Tumors (pNET): The median progression-free survival for patients with pNET treated with Sutent is around 10.2 months, compared to 5.4 months with placebo.
Adjuvant Treatment of RCC: In high-risk patients after nephrectomy, Sutent has demonstrated a median disease-free survival of approximately 6.8 years, significantly longer than the placebo group.